Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) bets on Firdapse

1
1026

Dallas, Texas 10/07/2013 (Financialstrend) – On September 5, Catalyst Pharmaceutical Partners, Inc. (NASDAQ:CPRX) announced that it is planning to offer 8.8 million shares of its common stock in order to raise funds to the tune of $14.2 million after expenses. The offer price has been fixed at $1.98 per share. Post this offering, a total of 52.8 million shares of outstanding common stock would be left in the company treasury.

 The development stage pharmaceutical firm has plans of using the proceeds of the sale into continuing the clinical trial of its three strong target drugs “Firdapse”, CPP-115 and CPP-109.

The company bought the North American licenses of Fridapse from BioMarin in October 2003. The drug is a proprietary combination of “amifampridine phosphate”. It is chemically named “3,4-diaminopyridine phosphate”. As part of the licensing agreement CPRX had agreed to foot the bill for the testing of this drug through the next phases of clinical trial. Hence CPRX is now working on handholding the test drug through the Phase 3 clinical testing for effectiveness to treat “Myasthenic Syndrome” the symptoms of which include acute muscle weakness.

 The phase 3 trial involves  36-patients who are spread across twelve cities in United States and Europe. The scope of the trail is expected to increase by an additional 15 sites covering South America and Canada. As per published timelines, the results for this critical phase of testing will be out by second quarter of 2014. CPRX is racing against time to successfully conclude the testing since the “Amifampridine phosphate” composition has been earmarked as a Orphan Drug by the U.S. Food & Drug Administration. The orphan drag tab covers the treatment of treat “Myasthenic Syndrome”. Hence if CPRX does come out with a successful trail results leading to a patent on Firdapse before any other firm, then they will be entitled to an “exclusive seven-year marketing window” to sell that drug.

This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.